Ewing's Sarcoma Presenting with Pulmonary Metastases at Diagnosis
This protocol addresses the management of Ewing's sarcoma in patients who present with pulmonary metastases at the time of initial diagnosis — a subgroup that requires simultaneous systemic and site-specific planning from the outset.
Clinical Scenario
Approximately 25% of Ewing's sarcoma patients present with metastatic disease at diagnosis; pulmonary involvement accounts for around 10% of all cases. The presence of lung metastases at diagnosis shapes the entire treatment strategy, including both local and systemic components.
Treatment Approach (Overview)
Management involves neoadjuvant induction chemotherapy with an interval-compressed regimen, followed by local therapy for the primary tumour. The full treatment sequence — including consolidation and the approach to metastatic sites — is detailed in the complete protocol.
Treatment Goals
- Complete histological tumour response on surgical specimen assessment
- Reduction in size of soft tissue mass on MRI
- Complete remission of all lung metastases
References
DOI: 10.1016/j.annonc.2021.08.1995
- Approximately 25% of patients are diagnosed with metastatic disease (10%: lung; 10%: bones/bone marrow; 5%: combinations or others).
- Patients with metastases at diagnosis are treated with the same treatment approach as patients with localised disease, but have a worse prognosis.
- The interval-compressed VDC/IE regimen showed superiority to VIDE for both event-free survival and OS, with similar toxicity, and it is currently the preferred first-line treatment in ES [I, B].
- Local treatment, especially in the presence of responding metastatic disease, has been proved to be associated with outcome improvement, and should therefore be attempted [II, B].
- Whole-lung irradiation, particularly when achieving complete remission of all lung metastases, can be used in this setting, although data demonstrating an improvement in outcome are lacking [III, C].
- Recent studies suggest that 100% response is most optimal to define a good tumour response in ES.
- Change in the size of the soft tissue mass is easily evaluated on MRI, a good predictor of tumour response.